Humanized mouse model of thrombosis is predictive of the clinical efficacy of antiplatelet agents

Circulation

Volumn 123, Issue 3, 2011, Pages 319-326

  Magallon, Jorge ^a   Chen, Jianchun ^b   Rabbani, Leroy ^a   Dangas, George ^a   Yang, Jing ^d   Bussel, James ^e   Diacovo, Thomas ^b,c  

^a Division of Cardiology   (United States)

^b Division of Neonatology   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

cell adhesion molecules; drugs; platelets; thrombosis; von Willebrand factor

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; EPTIFIBATIDE; PURINERGIC P2Y12 RECEPTOR; TIROFIBAN; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTICLE; BLOOD CLOTTING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; IC 50; MALE; MOUSE; MUTANT; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOCYTE; THROMBOSIS; THROMBUS; WILD TYPE;

ANIMALS; BIOLOGICAL MARKERS; CELL ADHESION; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; HUMANS; MICE; MICE, 129 STRAIN; MICE, MUTANT STRAINS; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET TRANSFUSION; PREDICTIVE VALUE OF TESTS; RECEPTORS, PURINERGIC P2Y12; SPECIES SPECIFICITY; THROMBOSIS; TICLOPIDINE; TRANSPLANTATION, HETEROLOGOUS; VON WILLEBRAND FACTOR;

EID: 79251563498     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.951970     Document Type: Article

References (44)

1. Van Zanten GH, de Graaf S, Slootweg PJ, Heijnen HF, Connolly TM, de Groot PG, Sixma JJ. Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest. 1994;93:615-632.
2. Furie B, Furie BC. Mechanisms of thrombus formation. N Eng J Med. 2008;359:938-949.
3. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res. 2007;100:1673-1685.
4. Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to the subendothelium. Nature. 1979;279:636-638.
5. Pietu G, Meulien P, Cherel G, Diaz J, Baruch D, Courtney M, Meyer D. Production in Escherichia coli of a biologically active subfragment of von Willebrand factor corresponding to the platelet glycoprotein Ib, collagen and heparin binding domains. Biochem Biophys Res Commun. 1989;164: 1339-1347.
6. Sugimoto M, Ricca G, Hrinda ME, Schreiber AB, Searfoss GH, Bottini E, Ruggeri ZM. Functional modulation of the isolated glycoprotein Ib binding domain of von Willebrand factor expressed in Escherichia coli. Biochemistry. 1991;30:5202-5209.
7. Kasirer-Friede A, Kahn ML, Shattil SJ. Platelet integrins and immuno-receptors. Immunol Rev. 2007;218:247-264.
8. Abrams CS. Intracellular signaling in platelets. Curr Opin Hematol. 2005;12:401-405.
9. Offermanns S. Activation of platelet function through G protein- coupled receptors. Circ Res. 2006;99:1293-1304.
10. Cattaneo M. New P2Y(12) inhibitors. Circulation. 2010;121:171-179.
11. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010;9:154-169.
12. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:199S-233S. (Pubitemid 351894914)
13. Schrör K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonist. J Thromb Thrombolysis. 2003;15:71-80.
14. Leadley RJ Jr, Chi L, Rebello SS, Gagnon A. Contribution of in vivo models of thrombosis to the discovery and development of novel anti-thrombotic agents. J Pharmacol Toxicol Methods. 2000;43:101-116.
15. Macchiarini F, Manz MG, Palucka AK, Shultz LD. Humanized mice: are we there yet? J Exp Med. 2005;202:1307-1311.
16. Napoli C, De Nigris F, Pignalosa O, Lerman A, Sica G, Fiorito C, Sica V, Chade A, Lerman LO. In vivo veritas: thrombosis mechanisms in animal models. Scand J Clin Lab Invest. 2006;66:407-427.
17. Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ, Collen D, Coller BS. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plas-minogen activator in dogs. J Clin Invest. 1988;81:1284-1291.
18. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation. 1988;77:670-677.
19. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258-264.
20. Chen J, Tan K, Zhou H, Lo HF, Roux DT, Liddington RC, Diacovo TG. Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies. Nat Biotechnol. 2008;26: 114-119.
21. Kushner FG, Hand M, Smith SC Jr, King SB III, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54:2205-2241.
22. Mousa SA, Kapil R, Mu DX. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459. Arterioscler Thromb Vasc Biol. 1999;19: 2535-2541.
23. Salles II, Feys HB, Iserbyt BF, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Inherited traits affecting platelet function. Blood Rev. 2008; 22:155-172.
24. Hurford MT, Sebastiano C. Hermansky-Pudlak syndrome: report of a case and review of the literature. Int J Clin Exp Pathol. 2008;1:550-554.
25. Doggett TA, Girdhar G, Lawshe A, Schmidtke DW, Laurenzi IJ, Diamond SL, Diacovo TG. Selectin-like kinetics and biomechanics promote rapid platelet adhesion in flow: the GPIba-VWF tether bond. Biophys J. 2002;83:194-205.
26. Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, Zirngibl H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood. 2000;96: 2520-2527.
27. Bagiella E, Sloan RP, Heitjan DF. Mixed-effects models in psychophys-iology. Psychophysiology. 2000;37:13-20.
28. Muller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schomig A, Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001; 85:92-93. (Pubitemid 32973418)
29. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood. 2008;112:3011-3025.
30. Quinn MJ, Byzova TV, Qin J, Topol EJ, Plow EF. Integrin alphaI-Ibbeta3 and its antagonism. Arterioscler Thromb Vasc Biol. 2003;23: 945-952.
31. Bennett JS, Berger BW, Billings PC. The structure and function of platelet integrins. J Thromb Haemost. 2009;7:200-205.
32. Matzdorff AC, Kühnel G, Kemkes-Matthes B, Voss R. Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer. J Thromb Thrombolysis. 2001;12:129-139.
33. Dickfeld T, Ruf A, Pogatsa-Murray G, Muller I, Engelmann B, Taubitz W, Fischer J, Meier O, Gawaz M. Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists. Thromb Res. 2001; 101:53-64.
34. Denis CV, Wagner DD. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler Thromb Vasc Biol. 2007;27: 728-739.
35. Artoni A, Li J, Mitchell B, Ruan J, Takagi J, Springer TA, French DL, Coller BS. Integrin beta3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. Proc Natl Acad Sci USA. 2004;101:13114-13120.
36. Harfenist EJ, Packham MA, Mustard JF. Effects of the cell adhesion peptide, Arg-Gly-Asp-Ser, on responses of washed platelets from humans, rabbits, and rats. Blood. 1988;71:132-136.
37. Jennings LK, White MM, Mandrell TD. Interspecies comparison of platelet aggregation, LIBS expression and clot retraction: observed differences in GPIIb-IIIa functional activity. Thromb Haemost. 1995;74: 1551-1556.
38. Basani RB, Zhu H, Thornton MA, Soto CS, Degrado WF, Kowalska MA, Bennett JS, Poncz M. Species differences in small molecule binding to alpha IIb beta 3 are the result of sequence differences in 2 loops of the alpha IIb beta propeller. Blood. 2009;113:902-910.
39. Kamata T, Tieu KK, Irie A, Springer TA, Takada Y. Amino acid residues in the alpha IIb subunit that are critical for ligand binding to integrin alpha IIbbeta 3 are clustered in the beta-propeller model. J Biol Chem. 2001;276:44275-44283.
40. Mehta SR, Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol. 2003;41:79S-88S.
41. Angiolillo DJ, Singh D. Clopidogrel for up to one year after PCI is cost-effective for people with acute coronary syndromes. Evid Based Cardiovasc Med. 2006;10:116-118.
42. Capodanno D, Angiolillo DJ. Platelet monitoring for PCI: which test is the one to choose? Hamostaseologie. 2009;29:376-380.
43. Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Palisaitis DA, Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J. 2008;29:2877-2885.
44. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007;115:3156-3164.